Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease [Corrigendum]

Novakovic D, Feligioni M, Scaccianoce S, et al. Drug Des Devel Ther. 2013;7:1359–1364.On page 1362, left hand column, last sentence under Functional studies:The effects of gantenerumab on cognitive assessment in the Morris water maze test were inconclusive, as both wild-type and transgeni...

Full description

Bibliographic Details
Main Authors:	Novakovic D, Feligioni M, Scaccianoce S, Caruso A, Piccinin S, Schepisi C, Errico F, Mercuri NB, Nicoletti F, Nisticò R
Format:	Article
Language:	English
Published:	Dove Medical Press 2014-05-01
Series:	Drug Design, Development and Therapy
Online Access:	http://www.dovepress.com/corrigendum-profile-of-gantenerumab-and-its-potential-in-the-trea-peer-reviewed-article-DDDT

Similar Items

Profile of gantenerumab and its potential in the treatment of Alzheimer's disease
by: Novakovic D, et al.
Published: (2013-11-01)

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
by: Susanne Ostrowitzki, et al.
Published: (2017-12-01)

Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
by: Susanne Ostrowitzki, et al.
Published: (2018-09-01)

Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis
by: Gregory Klein, et al.
Published: (2019-12-01)

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
by: Martin Tolar, et al.
Published: (2020-08-01)

Risk Factors for Alzheimer’s Disease: Focus on Stress
by: Alessandra Caruso, et al.
Published: (2019-09-01)

Serum miR-128 Serves as a Potential Diagnostic Biomarker for Alzheimer’s Disease [Corrigendum]
by: Zhang M, et al.
Published: (2021-02-01)

Legal medical consideration of Alzheimer’s disease patients’ dysgraphia and cognitive dysfunction a 6 month follow up
by: Onofri E, et al.
Published: (2016-03-01)

Cognitive fluctuations in connection to dysgraphia: a comparison of Alzheimer’s disease with dementia Lewy bodies
by: Onofri E, et al.
Published: (2015-03-01)

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease [Corrigendum]
by: Hager K, et al.
Published: (2014-10-01)

Neuroinflammation in Alzheimer’s disease
by: Zhang FJ, et al.
Published: (2015-01-01)

Olfactory dysfunction in Alzheimer’s disease
by: Zou YM, et al.
Published: (2016-04-01)

Role of berberine in Alzheimer’s disease
by: Cai Z, et al.
Published: (2016-10-01)

Targeting neuroinflammation in Alzheimer’s disease
by: Bronzuoli MR, et al.
Published: (2016-11-01)

Response to Alzheimer’s research paper
by: Tait HM
Published: (2013-05-01)

Cytological and cytometric analysis of oral mucosa in patients with Alzheimer’s and Parkinson’s disease
by: Kose Ozlece H, et al.
Published: (2018-07-01)

Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics
by: Tiwari S, et al.
Published: (2019-07-01)

Magnetic resonance spectroscopy in Alzheimer’s disease
by: Graff-Radford J, et al.
Published: (2013-05-01)

Clinical neurorestorative progress in Alzheimer’s disease
by: Qiao L, et al.
Published: (2014-12-01)

Curcumin: a natural substance with potential efficacy in Alzheimer’s disease
by: Potter PE
Published: (2013-05-01)

Caregiver burden and coping strategies in caregivers of patients with Alzheimer’s disease
by: Iavarone A, et al.
Published: (2014-07-01)

Systematic review of the association between Alzheimer’s disease and chronic glaucoma
by: Janssen SF, et al.
Published: (2015-05-01)

Altered diastolic function and aortic stiffness in Alzheimer’s disease
by: Çalık AN, et al.
Published: (2014-07-01)

Research progress in animal models and stem cell therapy for Alzheimer’s disease
by: Han F, et al.
Published: (2014-12-01)

Liposome delivery systems for the treatment of Alzheimer’s disease
by: Ross C, et al.
Published: (2018-12-01)

What are the links between hypoxia and Alzheimer’s disease?
by: Lall R, et al.
Published: (2019-05-01)

Late onset Alzheimer’s disease in older people
by: Ahmet Turan Isik
Published: (2010-10-01)

Cerebral blood flow in Alzheimer&rsquo;s disease
by: Roher AE, et al.
Published: (2012-10-01)

The occurrence of cerebrovascular atherosclerosis in Alzheimer’s disease patients
by: Yuan J, et al.
Published: (2013-05-01)

Cerebral small vessel disease and Alzheimer’s disease
by: Cai Z, et al.
Published: (2015-10-01)

Update on the use of memantine in Alzheimer&rsquo;s disease
by: Robert J van Marum
Published: (2009-03-01)

Personalizing the Care and Treatment of Alzheimer’s Disease: An Overview
by: Svob Strac D, et al.
Published: (2021-05-01)

RAB10: an Alzheimer’s disease resilience locus and potential drug target
by: Tavana JP, et al.
Published: (2018-12-01)

Telepharmacy: a pharmacist’s perspective on the clinical benefits and challenges [Corrigendum]
by: Poudel A, et al.
Published: (2016-11-01)

Importance of hypoglycemia on the risk of Alzheimer’s disease in elderly subjects with diabetes mellitus
by: Muratli S, et al.
Published: (2015-11-01)

Targeting Impaired Antimicrobial Immunity in the Brain for the Treatment of Alzheimer’s Disease
by: Fulop T, et al.
Published: (2021-05-01)

Ceruloplasmin and iron in Alzheimer&rsquo;s disease and Parkinson&rsquo;s disease: a synopsis of recent studies
by: Kristinsson J, et al.
Published: (2012-11-01)

Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer&rsquo;s disease in daily practice
by: Seibert J, et al.
Published: (2012-04-01)

Spaced Retrieval and Episodic Memory Training in Alzheimer’s Disease
by: Small JA, et al.
Published: (2020-04-01)

Advances with RNA interference in Alzheimer&rsquo;s disease research
by: Chen S, et al.
Published: (2013-02-01)